472 research outputs found
Waging war against pancreatic cancer: an interview with David Tuveson
No full textDavid Tuveson, Director of the Cancer Center at Cold Spring Harbor Laboratory, is a clinician-scientist with a longstanding interest in understanding and treating pancreatic cancer. Since developing the first mouse model of pancreatic cancer in 2002, the Tuveson lab has made a series of discoveries that shed light on the molecular drivers of this disease and provide promising therapeutic avenues for a malignancy that is notoriously challenging to treat. In collaboration with Hans Clevers, David developed the first pancreatic cancer organoids, which revolutionized the field by providing a powerful model system for basic discoveries and advancement of personalized medicine. Here, David talks to Ross Cagan about his path from chemistry student to world-renowned oncologist, highlighting how his colleagues, mentors and patient interactions shaped his research interests and unique approach to scientific discovery. As well as discussing the story behind some of his breakthroughs, he provides tips on running a lab and succeeding in or outside academia
Waging war against pancreatic cancer: an interview with David Tuveson
No full textDavid Tuveson, Director of the Cancer Center at Cold Spring Harbor Laboratory, is a clinician-scientist with a longstanding interest in understanding and treating pancreatic cancer. Since developing the first mouse model of pancreatic cancer in 2002, the Tuveson lab has made a series of discoveries that shed light on the molecular drivers of this disease and provide promising therapeutic avenues for a malignancy that is notoriously challenging to treat. In collaboration with Hans Clevers, David developed the first pancreatic cancer organoids, which revolutionized the field by providing a powerful model system for basic discoveries and advancement of personalized medicine. Here, David talks to Ross Cagan about his path from chemistry student to world-renowned oncologist, highlighting how his colleagues, mentors and patient interactions shaped his research interests and unique approach to scientific discovery. As well as discussing the story behind some of his breakthroughs, he provides tips on running a lab and succeeding in or outside academia.</jats:p
Interview with Dr. Tuveson from <i>nab</i>-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
No full textmp3 file (10 MB). In the March edition of the Cancer Discovery podcast, Executive Editor Mark Landis talks with David A. Tuveson about his paper, which provides mechanistic insight into the clinical cooperation observed between gemcitabine and nab-paclitaxel in the treatment of pancreatic cancer.</p
The RAS and YAP1 dance, who is leading?
No full textThe Hippo‐signaling effector YAP1 was recently found to compensate for oncogenic RAS in certain neoplasms, suggesting so far unanticipated molecular interplays between these major signaling routes. A new study in this issue of The EMBO Journal details KRAS‐dependent control of YAP1 stability as well as positive feedback regulation via the RAS/YAP1/EGFR‐ligand axis as novel molecular mechanisms that could become exploitable for therapeutic strategies
Stromal biology and therapy in pancreatic cancer: a changing paradigm
No full textPancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours and poses an unsolved problem in cancer medicine. Despite the recent success of two combination chemotherapies for palliative patients, the modest survival benefits are often traded against significant side effects and a compromised quality of life. Although the molecular events underlying the initiation and progression of PDA have been intensively studied and are increasingly understood, the reasons for the poor therapeutic response are hardly apprehended. One leading hypothesis over the last few years has been that the pronounced tumour microenvironment in PDA not only promotes carcinogenesis and tumour progression but also mediates therapeutic resistance. To this end, targeting of various stromal components and pathways was considered a promising strategy to biochemically and biophysically enhance therapeutic response. However, none of the efforts have yet led to efficacious and approved therapies in patients. Additionally, recent data have shown that tumour-associated fibroblasts may restrain rather than promote tumour growth, reinforcing the need to critically revisit the complexity and complicity of the tumour-stroma with translational implications for future therapy and clinical trial design
Supp_Mat_for_Development_of_Primary_Pancreatic_Organoid_Tumor_Models_for_HT_Pheno_Drug_Screening_by_Hue_et_al – Supplemental material for Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening
No full textSupplemental material, Supp_Mat_for_Development_of_Primary_Pancreatic_Organoid_Tumor_Models_for_HT_Pheno_Drug_Screening_by_Hue_et_al for Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening by Shurong Hou, Hervé Tiriac, Banu Priya Sridharan, Louis Scampavia, Franck Madoux, Jan Seldin, Glauco R. Souza, Donald Watson, David Tuveson, and Timothy P. Spicer in SLAS Discovery</p
Immigration in science
No full textThe advance of science is dependent upon collaboration, which does not have a visa attached to it. Indeed, over 40% of all American-based Nobel Prize winners are immigrants, and data from the National Science Foundation show that 49% of postdocs and 29% of science and engineering faculty in the US are foreign-born. However, restrictive new immigration policies in the US have left many scientists deeply concerned about their future and many American-based laboratories worried about attracting the best talent. At JEM, we're celebrating immigration by sharing the experiences of immigrant and nonimmigrant scientists on our editorial board. Alexander Rudensky and Jean-Laurent Casanova give their firsthand perspective on immigrating to the US, while Jedd Wolchok, Carl Nathan, David Holtzman, Susan Kaech, Lewis Lanier, and David Tuveson reflect on how immigration has affected their laboratories
Surmonter la résistance thérapeutique pour vaincre le cancer / Overcoming therapeutic resistance to defeat cancer
No full textSéminaire FSER organisé par David Tuveson (Cold Spring Harbor Laboratory, USA) et Neal Rosen (Memorial Sloan-Kettering Cancer Center, New York, USA) du 27 juin au 2 juillet 2014 Participants Julien Ablain, Laura Attardi, Alberto Bardelli, Glenn Dranoff, Mikala Egeblad, Jeffrey A. Engelman, Gerard Evan, Shridar Ganesan, Joseph Jonkers, Anthony Letai, Richard Marais, Frank McCormick, Benjamin Neel, Scott Powers, Neal Rosen, Louis M. Staudt, Hugues de Thé, David Tuveson, Matthew G. Vander Heiden..
- …
